2023
The Science of Precision Prevention Research Opportunities and Clinical Applications to Reduce Cardiovascular Health Disparities
Pearson T, Vitalis D, Pratt C, Campo R, Armoundas A, Au D, Beech B, Brazhnik O, Chute C, Davidson K, Diez-Roux A, Fine L, Gabriel D, Groenveld P, Hall J, Hamilton A, Hu H, Ji H, Kind A, Kraus W, Krumholz H, Mensah G, Merchant R, Mozaffarian D, Murray D, Neumark-Sztainer D, Petersen M, Goff D. The Science of Precision Prevention Research Opportunities and Clinical Applications to Reduce Cardiovascular Health Disparities. JACC Advances 2023, 3: 100759. PMID: 38375059, PMCID: PMC10876066, DOI: 10.1016/j.jacadv.2023.100759.Peer-Reviewed Original ResearchCardiovascular health disparitiesPrecision preventionHealth disparitiesHealth equity gapCardiovascular disease disparitiesPrevention intervention researchCardiovascular healthSocial determinantsDisease disparitiesPreventionClinical applicationImplementation scienceIntervention researchHealthDisparitiesCurrent gapsEquity gapIndividualsTrials
2022
Clinical decision support in cardiovascular medicine
Lu Y, Melnick ER, Krumholz HM. Clinical decision support in cardiovascular medicine. The BMJ 2022, 377: e059818. PMID: 35613721, DOI: 10.1136/bmj-2020-059818.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseCardiovascular careEffectiveness of CDSRisk factor modificationClinical decision support toolQuality of careClinical decision supportClinical outcomesFactor modificationHealth information technologyClinical practicePatient careDiseaseCardiovascular medicineCDS effectivenessCareEffectiveness of deliveryMissed opportunityTreatmentFailureProper evidenceHealthcare processesMedicineEvidencePrevention
2021
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 78: 1635-1654. PMID: 34649702, PMCID: PMC8504484, DOI: 10.1016/j.jacc.2021.08.021.Peer-Reviewed Original ResearchConceptsLipid-modulating agentsEndothelial activationLow high-density lipoprotein cholesterolCOVID-19High-density lipoprotein cholesterolLipid modulating agentsHigh triglyceride levelsMultiorgan manifestationsStatin trialsLipoprotein cholesterolSystemic inflammationTriglyceride levelsJACC StateWorse outcomesInflammatory responsePatient managementRCTsCoronavirus diseaseViral entrySystematic searchLipid raft disruptionTrialsPatientsRaft disruptionPrevention
2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2010
Applying Practice Recommendations for the Prevention and Treatment of Obesity in Children and Adolescents
Dorsey KB, Mauldon M, Magraw R, Valka J, Yu S, Krumholz HM. Applying Practice Recommendations for the Prevention and Treatment of Obesity in Children and Adolescents. Clinical Pediatrics 2010, 49: 137-145. PMID: 20080520, DOI: 10.1177/0009922809346567.Peer-Reviewed Original ResearchConceptsCross-sectional analysisObese patientsFifth visitDocumentation of BMIFirst clinic visitTreatment of obesityLongitudinal analysisIndividual risk behaviorsClinic visitsClinician adherenceMedical recordsWeight managementObesity preventionFirst visitClinicians' attentionRisk behaviorsPatientsPractice recommendationsVisitsOverweightBMIPreventionAdherenceTreatmentObesity
2006
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation 2006, 113: 2363-2372. PMID: 16702489, DOI: 10.1161/circulationaha.106.174516.Peer-Reviewed Original ResearchAHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute
Smith S, Allen J, Blair S, Bonow R, Brass L, Fonarow G, Grundy S, Hiratzka L, Jones D, Krumholz H, Mosca L, Pasternak R, Pearson T, Pfeffer M, Taubert K. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute. Journal Of The American College Of Cardiology 2006, 47: 2130-2139. PMID: 16697342, DOI: 10.1016/j.jacc.2006.04.026.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCardiovascular AgentsCoronary Artery DiseaseDiabetes MellitusDyslipidemiasHealth BehaviorHematologic AgentsHumansHypertensionHypolipidemic AgentsInfluenza VaccinesMineralocorticoid Receptor AntagonistsMotor ActivityObesitySmoking Cessation
2003
Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint
Foody JM, Krumholz HM. Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal Of Geriatric Cardiology 2003, 12: 357-360. PMID: 14610384, DOI: 10.1111/j.1076-7460.2003.02912.x.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePrimary preventionArtery diseaseOvert coronary artery diseaseRisk of myositisCardiovascular disease eventsRole of statinsUse of statinsAge 65 yearsBalance of risksCardiovascular eventsStatin therapyPatient preferencesCholesterol levelsCardiovascular diseaseOctogenariansClinical uncertaintyDisease eventsCurrent evidenceStatinsAge groupsDiseasePreventionRiskMyositis
2001
Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction
Krumholz HM, Chen YT, Wang Y, Radford MJ. Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction. JAMA Internal Medicine 2001, 161: 538-544. PMID: 11252112, DOI: 10.1001/archinte.161.4.538.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionInteraction of aspirinEnzyme inhibitorsAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsElderly patientsSecondary preventionRandomized trialsElderly survivorsLower riskAspirinPatientsMultivariate analysisHospitalizationMortalityMedicationsInfarctionInhibitorsTherapySurvivorsTrialsPrevention
1997
Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee.
Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, Houston-Miller N, Kris-Etherton P, Krumholz H, LaRosa J, Ockene I, Pearson T, Reed J, Washington R, Smith S. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997, 95: 2329-31. PMID: 9142014, DOI: 10.1161/01.cir.95.9.2329.Peer-Reviewed Original Research